How much is DermBiont worth in 2026?

DermBiont has a current valuation of N/A based on their Later Stage VC (Series B) round and secondary market data.

How much funding has DermBiont raised?

DermBiont has raised N/A in total funding across 4 funding rounds.

DermBiont

Drug Discovery

DermBiont valuation and funding history | Last updated: October 24, 2023 | 4 funding rounds

Current Valuation

N/A

As of October 24, 2023

Total Funding Raised

N/A

Across 4 rounds

Last Round

Later Stage VC (Series B)

$35.2M

Last Funding

Oct 2023

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
October 24, 2023	Later Stage VC (Series B)	$35.2M	N/A	-
December 17, 2021	Early Stage VC (Series A2)	$35.4M	N/A	-
October 29, 2020	Early Stage VC (Series A2)	$7.2M	N/A	-
June 18, 2019	Early Stage VC (Series A)	$8.8M	N/A	-

Valuation Analysis

Current Valuation Metrics

DermBiont is currently valued at N/A as of October 24, 2023.

Track DermBiont Valuation Updates

Get notified when DermBiont raises new funding or valuation changes

Explore More Data

Detailed analysis for DermBiont

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock DermBiont's valuation history, funding rounds, and growth metrics.

No credit card required

What is DermBiont Worth in 2026?

DermBiont is a leading private company in the Drug Discovery sector. Track DermBiont's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How DermBiont Valuation is Determined

Private company valuations like DermBiont's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.